Key statistics
As of last trade, Arrowhead Pharmaceuticals Inc (HDP1:BER) traded at 15.48, 76.45% above the 52 week low of 8.77 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.48 |
---|---|
High | 15.48 |
Low | 15.48 |
Bid | 15.97 |
Offer | 16.04 |
Previous close | 16.09 |
Average volume | 239.29 |
---|---|
Shares outstanding | 138.10m |
Free float | 118.88m |
P/E (TTM) | -- |
Market cap | 2.53bn USD |
EPS (TTM) | -1.38 USD |
Data delayed at least 15 minutes, as of Jul 14 2025 07:08 BST.
More ▼
- Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
- Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
- Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
- Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
- Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
- Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
- Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
More ▼